New drug shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT05216835
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-stage trial tested a new drug called AZD7789 in 45 people whose Hodgkin lymphoma had returned or stopped responding to at least two prior treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The main goals were to check safety and find the right dose, with early signs of tumor shrinkage also measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Toronto, Ontario, M5G 1X6, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
København Ø, 2100, Denmark
-
Research Site
Lille, 59037, France
-
Research Site
Bologna, 40138, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Valencia, 46010, Spain
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, 0X3 7LJ, United Kingdom
Conditions
Explore the condition pages connected to this study.